MedTrace Logo

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

NCT05642806 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-04-17

No results posted yet for this study

Summary

This study aims to analyze the immune profiles of patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) with and without asthma before and after Mepolizumab.

A group of participants with CRS without nasal polyps (CRSsNP) with asthma will be included to compare their immune profiles to CRSwNP.

Conditions

Interventions

BIOLOGICAL

Mepolizumab

Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

OTHER

Placebo

Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

Sponsors & Collaborators

  • St. Paul's Sinus Centre

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-12-30
Completion
2025-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05642806 on ClinicalTrials.gov